Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era

Front Pharmacol. 2021 Apr 16:12:623674. doi: 10.3389/fphar.2021.623674. eCollection 2021.

Abstract

Targeted therapy refers to exploiting the specific therapeutic drugs against the pathogenic molecules (a protein or a gene) or cells. The drug specifically binds to disease-causing molecules or cells without affecting normal tissue, thus enabling personalized and precision treatment. Initially, therapeutic drugs included antibodies and small molecules, (e.g. nucleic acid drugs). With the advancement of the biology technology and immunotherapy, the gene editing and cell editing techniques are utilized for the disease treatment. Currently, targeted therapies applied to treat cardiovascular diseases (CVDs) mainly include protein drugs, gene editing technologies, nucleic acid drugs and cell therapy. Although targeted therapy has demonstrated excellent efficacy in pre-clinical and clinical trials, several limitations need to be recognized and overcome in clinical application, (e.g. off-target events, gene mutations, etc.). This review introduces the mechanisms of different targeted therapies, and mainly describes the targeted therapy applied in the CVDs. Furthermore, we made comparative analysis to clarify the advantages and disadvantages of different targeted therapies. This overview is expected to provide a new concept to the treatment of the CVDs.

Keywords: antibody; cardiovascular disease; cell therapy; gene editing; nucleic acid drugs; targeted therapy.

Publication types

  • Review

Grants and funding

This work was supported by Fundamental Research Funds for the Central Universities, Innovation Fund for Medical Sciences (CIFMS, 2016-I2M-1-015).